Company news
Ondine Biomedical, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Ondine completes successful SARS-CoV-2 trial
July 19, 2022
Posting of annual report
June 7, 2022
Full Year Results to 31 December 2021
May 19, 2022
WHO calls for better infection prevention
May 10, 2022
Photodisinfection effective against SARS-CoV-2
April 5, 2022
Grant of Options and PDMR Dealing
February 21, 2022
Ondine treats first patients in Phase 2 FDA trial
February 7, 2022
Ondine and University of Navarra initiate clinical
December 20, 2021
Ondine Biomedical appoints Professor Trevor Jones
December 15, 2021
Ondine Biomedical appoints new Board of Directors
December 7, 2021
Ondine Biomedical announces AIM market listing
December 6, 2021
Calls
The 5 newest of 9 calls. Every call is listed under its year.
- Ondine Biomedical (LSE:OBI) — Investor Presentation of Phase 3 Topline Results
Sep 10, 2026
Transcript - Ondine Biomedical (LSE:OBI) — Results for the year ended 31 December 2025
Jun 4, 2026
Transcript - Ondine Biomedical (LSE:OBI) — Interim financial results for the period ended 30 June 2025
Sep 26, 2025
Transcript - Ondine Biomedical (LSE:OBI) — Audited results for the year ended 31 December 2024
May 15, 2025
Transcript - Ondine Biomedical (LSE:OBI) — Half Year Results
Sep 30, 2024
Transcript